Relmada Therapeutics, Inc. RLMD Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s stock issuance proceeds?
- Relmada Therapeutics, Inc. (RLMD) reported stock issuance proceeds of $160M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s stock issuance proceeds changed year-over-year?
- Relmada Therapeutics, Inc.'s stock issuance proceeds increased by 583.5% year-over-year, from $23.41M to $160M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s stock issuance proceeds?
- Over 3 years (2021 to 2025), Relmada Therapeutics, Inc.'s stock issuance proceeds has grown at a -20.3% compound annual growth rate (CAGR), from $184.68M to $93.64M.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.